NCT04975256 - Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

November 2, 2022

Study Completion Date

November 15, 2022

Conditions

Advanced CancerMetastatic CancerMalignant Neoplasm of ColonMalignant Neoplasm of LungMalignant Neoplastic Disease

Interventions

DRUG

MRTX849

KRAS G12C inhibitor

DRUG

BI 1701963

SOS1 Inhibitor

Trial Locations (4)

The Cleveland Clinic Foundation, Cleveland

Washington University School of Medicine, St Louis

MD Anderson Cancer Center, Houston

Next Oncology, San Antonio